Erin H. Breese, MD, PhD
- Member, Division of Oncology
- Associate Professor, UC Department of Pediatrics
- erin.breese@cchmc.org
- Board Certified
About
Biography
My work at Cincinnati Children’s stems from a desire to improve the quality of life and outcomes for children fighting cancer. I am board certified in both pediatrics and pediatric hematology/oncology.
Understanding the molecular drivers of leukemia, the adaptations that leukemia cells develop to become resistant to chemotherapy and its interactions with a patient’s immune system are key factors to improving cancer therapies. Appropriate therapy for pediatric leukemia requires a precision medicine approach to tailor therapy for the individual patient. Our leukemia/lymphoma team is constantly working locally, nationally and internationally to improve our options for therapy and decrease associated toxicities.
My research areas of interest are infant leukemia, the molecular biology of leukemia, KMT2A-rearranged leukemia, precision medicine and clinical trial development for high-risk and relapsed leukemia.
PhD: Biochemistry & Molecular Biology, Indiana University, Indianapolis, IN, 2006.
MD: Indiana University, Indianapolis, IN, 2008.
Residency: Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, 2011.
Fellowship: Pediatric Hematology/Oncology, Stanford University School of Medicine, Lucile Packard Children’s Hospital, Palo Alto, CA, 2014.
Certification: American Board of Pediatrics, 2011; ABP Pediatric Hematology/Oncology, 2015.
Interests
Pediatric leukemia and lymphoma
Services and Specialties
Cancer and Blood Diseases, Leukemia
Interests
Molecular pathogenesis of leukemia; novel therapeutics for childhood leukemia, especially for infants with MLL-rearranged leukemia
Research Areas
Oncology, Cancer and Blood Diseases
Additional Languages
FrenchLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances. 2022; 6:4251-4255.
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatric Blood and Cancer. 2021; 68:e29126.
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. British Journal of Haematology. 2021; 193:1172-1177.
Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 2021; 43:152-154.
Acute Leukemia in Infants. Current Oncology Reports. 2021; 23:27.
Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38:e22502.
Experiences of a Multidisciplinary Genomic Tumor Board Interpreting Risk for Underlying Germline Variants in Tumor-Only Sequencing Results. JCO Precision Oncology. 2019; 3:1-8.
Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. Pediatric Blood and Cancer. 2019; 66:e27719.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey